Midatech Group Receives Regulatory Approval for Clinically Testing Ultra-small Gold Nanoparticles  
11/15/2011 6:48:07 AM

OXFORD, England--(BUSINESS WIRE)--Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.